wr 1065 has been researched along with Neoplasms in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (28.57) | 18.7374 |
1990's | 2 (28.57) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bykov, VJ; Selivanova, G; Wiman, KG | 1 |
Koukourakis, MI | 1 |
Capizzi, R | 1 |
Capizzi, RL | 1 |
Baruchel, S; Fouladi, M; Gammon, J; Grant, R; Greenberg, ML; Klein, J; Koren, G; Stempak, D | 1 |
Grdina, DJ; Nagy, B; Sigdestad, CP | 1 |
Bonner, HS; Glover, DJ; Kligerman, MM; Norfleet, AL; Shaw, LM; Turrisi, AT; Weiler, C | 1 |
5 review(s) available for wr 1065 and Neoplasms
Article | Year |
---|---|
Small molecules that reactivate mutant p53.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ellipticines; Gene Expression Regulation, Neoplastic; Genes, p53; Genetic Therapy; Humans; Mercaptoethylamines; Molecular Chaperones; Mutation; Neoplasms; Pyrimidines | 2003 |
Amifostine: is there evidence of tumor protection?
Topics: Amifostine; Animals; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Dogs; Drug Evaluation, Preclinical; Humans; Mercaptoethylamines; Models, Animal; Neoplasms; Organoplatinum Compounds; Radiation Injuries; Radiation-Protective Agents; Rats; Sarcoma | 2003 |
Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies.
Topics: Amifostine; Animals; Antineoplastic Agents; Cells; Combined Modality Therapy; Humans; Mercaptoethylamines; Neoplasms; Premedication | 1996 |
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
Topics: Amifostine; Animals; Antineoplastic Agents; Cytoprotection; Drug Evaluation, Preclinical; Humans; Mercaptoethylamines; Neoplasms; Neoplasms, Experimental; Prodrugs; Protective Agents; Radiation-Protective Agents; Tumor Cells, Cultured | 1999 |
Radioprotectors in treatment therapy to reduce risk in secondary tumor induction.
Topics: Amifostine; Animals; Cell Transformation, Neoplastic; Humans; Mercaptoethylamines; Neoplasms; Neoplasms, Radiation-Induced; Radiation-Protective Agents | 1988 |
1 trial(s) available for wr 1065 and Neoplasms
Article | Year |
---|---|
Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Male; Mercaptoethylamines; Neoplasms; Treatment Failure | 2001 |
1 other study(ies) available for wr 1065 and Neoplasms
Article | Year |
---|---|
Human pharmacokinetics of WR-2721.
Topics: Amifostine; Humans; Kinetics; Mercaptoethylamines; Neoplasms; Organothiophosphorus Compounds; Radiation-Protective Agents; Tissue Distribution | 1986 |